The group investigates the role of autophagy–lysosomal dysfunction in neurodegeneration, aging, and lysosomal storage disorders, integrating basic, clinical, and translational research approaches.

Our main research lines include:

• Mechanisms of autophagy–lysosomal dysfunction in neurodegeneration: studying how alterations in cellular clearance pathways, lipid metabolism, and protein homeostasis contribute to Parkinson’s disease and neurodegeneration.
• Clinical and biomarker research: identification and validation of biomarkers linked to autophagy–lysosomal pathways to enable patient stratification and support future lysosomal-targeting therapies.
• Therapeutic development targeting autophagy–lysosomal pathways: development of disease-modifying strategies aimed at restoring lysosomal function.
• NanoERT platform: development of nanotechnology-based enzyme replacement therapies for brain and systemic delivery of lysosomal enzymes, initially targeting GBA and being extended to other enzymes involved in lysosomal-related diseases.